不同剂量替加环素联合氨基糖苷类抗菌药治疗ICU耐药鲍曼不动杆菌引起的重症肺炎患者的效果

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of different doses of Tigecycline combined with aminoglycosides in the treatment of patients with severe pneumonia caused by ICU-resistant Acinetobacter baumannii.Methods A total of 90 patients with severe pneumonia caused by ICU-resistant Acinetobacter baumannii treated in our hospital from July 2016 to July 2019 were selected as the research object, according to random number table method, they were divided into the control group and the study group, 45 cases in each group.The control group was treated with conventional doses of Tigecycline combined with aminoglycoside antibacterials, and the study group was treated with high doses of Tigecycline combined with aminoglycoside antibacterials.The bacterial clearance rate, SOFA score, APACHE Ⅱscore,the incidence rate of adverse reaction and mortality between the two groups were compared.Results The bacterial clearance rate of patients in the study group was higher than that in the control group, and the differences was statistically significant (P＜0.05).The SOFA score, APACHE Ⅱscore and mortality rate of the study group were lower than those of the control group, and the differences were statistically significant (P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05).Conclusion High dose Tigecycline combined with aminoglycosides in the treatment of patients with severe pneumonia caused by ICU-resistant Acinetobacter baumannii has good effect, which can significantly improve the body′s bacterial clearance rate, and reduce the mortality of patients, it has high drug safety, which is worthy of clinical promotion.

Key words： Tigecycline Aminoglycosides ICU-resistant Acinetobacter baumannii Severe pneumonia Multiple organ protection

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SU Hang
	GANG Li

Cite this article:

SU Hang,GANG Li. Effect of different doses of Tigecycline combined with aminoglycoside antibacterials in the treatment of patients with severe pneumonia caused by ICU-resistant Acinetobacter baumannii[J]. 中国当代医药, 2020, 27(23): 47-49.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I23/47

[12]	何巍，穆晓东，加慧.血必净注射液联合替加环素治疗鲍曼不动杆菌肺部感染的临床效果[J].中国当代医药，2019，26（5）：31-33，37.
[1]	孟伟，吴大玮，单悌超，等.替加环素治疗重症患者呼吸机相关性肺炎[J].山东大学学报（医学版），2017，55（4）：71-75.
[2]	冯磊，余肆崇，张小裔.替加环素联合阿米卡星治疗ICU耐药鲍曼不动杆菌相关性肺炎患者的效果及对血清PCT、IL-6、CRP的影响[J].内科，2017，12（6）：34-36.
[3]	崔自芳.机械通气联合氨溴索对老年脑卒中后重症肺炎的影响[J].中国实用神经疾病杂志，2017，20（15）：94-96.
[4]	闫芳，陈倪，杨芳，等.大蒜素治疗细菌感染所致呼吸机相关性肺炎的临床研究[J].湖南中医药大学学报，2017，37（3）：313-316.
[5]	杨阳.对入住ICU的重症肺炎患者使用乌司他丁进行治疗的效果探析[J].当代医药论丛，2018，16（22）：116-118.
[6]	中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志，2006，29（10）：651-655.
[7]	陈涛，蔡龙，张霞辉，等.替加环素不同治疗方案对ICU泛耐药鲍曼不动杆菌肺部感染的临床效果对比观察[J].当代医学，2018，24（34）：154-156.
[8]	龚蕉椒，李锐，郭华，等.神经内科重症监护病房卒中后鲍曼不动杆菌院内感染的危险因素分析[J].现代医院，2018，18（1）：90-91，95.
[9]	钟雪，冯婉玉.替加环素单药与联合方案治疗多重耐药菌感染疗效对比的系统评价[J].中国抗生素杂志，2018，43（2）：17-24.
[10]	沈锋，吴彦其，王亚辉，等.CPIS评分指导ICU细菌性重症肺炎患者治疗能减少抗菌药物使用持续时间及使用频度[J].中华危重病急救医学，2019，31（5）：556-561.
[11]	张志生.替加环素在外科ICU难治性腹腔感染治疗中的应用价值分析[J].中国医药指南，2017，15（36）：75-76.
[13]	蓝大波，吴晓梁，徐良志.替加环素联合头孢哌酮钠舒巴坦钠治疗高龄多重耐药鲍曼不动杆菌肺炎患者的疗效及安全性分析[J].浙江创伤外科，2016，21（01）：62-64.
[14]	高金丹.替加环素治疗多重或泛耐药鲍曼不动杆菌引起的重症肺炎的疗效评价[D].杭州：浙江大学，2015.
[15]	许国斌，朱金强，张近波，等.替加环素联合头孢哌酮/舒巴坦治疗泛耐药鲍曼不动杆菌老年重症肺炎的临床疗效[J].中国老年学杂志，2016，36（7）：1649-1651.
[16]	倪文涛.替加环素联合氨基糖苷类抑制产KPC肺炎克雷伯菌耐药发生的体内外研究[D].北京：中国人民解放军医学院，2017.